Methylation status of the PPP1R13L promoter region among lung cancer patients and healthy controls
Analytical cross-sectional study
Keywords:
PPP1R13L protein, human [supplementary concept], Promoter region, genetic, CpG islands, Methylation, Lung neoplasmsAbstract
BACKGROUND: There is evidence that genetic predisposition and epigenetic alteration (e.g. DNA meth-ylation) play major roles in lung cancer. In our genetic epidemiological studies, rs1970764 in oncogene PPP1R13L was most consistently associated with lung cancer risk. Here, we explored the role of PPP1R13L methylation in lung cancer development. DESIGN AND SETTING: Analytical cross-sectional study (45 lung cancer cases and 45 controls), conduct-ed in China. METHODS: We investigated the DNA methylation status of 2,160 cytosine-phosphate-guanine (CpG) sites in the PPP1R13L promoter region using the EpiTYPER assay of the Sequenom MassARRAY platform. RESULTS: In the whole study group, the methylation levels of CpG-6, CpG-9, CpG-20 and CpG-21 were significantly lower and those of CpG-16 were significantly higher in cases than in controls. Among smok-ers, the methylation levels at five CpG sites (CpG-6, CpG-11, CpG-15, CpG-20 and CpG-21) were statistically significantly lower among cases. Among men, the methylation levels at four CpG sites (CpG-11, CpG-15, CpG-20 and CpG-21) were significantly lower among cases. Regarding smokers, the methylation levels at CpG-7.8 and CpG-21 among cases and at CpG-22 among controls were significantly lower, compared with nonsmokers. The frequency of positivity for methylation was not significantly different between lung cancer cases and controls (68.22% for cases and 71.87% for controls; P = 0.119). CONCLUSION: Our study on a Chinese population suggests that lung cancer patients have aberrant methylation status (hypomethylation tended to be more frequent) in peripheral blood leukocytes at sev-eral CpG sites in the PPP1R13L promoter region and that exposure to smoking may influence methyla-tion status.
Downloads
References
Ferlay J, Soerjomataram I, Dikshit R, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136(5):E359-86. PMID: 25220842; doi: 10.1002/ ijc.29210.
Cheng TY, Cramb SM, Baade PD, et al. The International Epidemiology of Lung Cancer: Latest Trends, Disparities, and Tumor Characteristics. J Thorac Oncol. 2016;11(10):1653-71. PMID: 27364315; doi: 10.1016/j. jtho.2016.05.021.
Langevin SM, Kratzke RA, Kelsey KT. Epigenetics of lung cancer. Transl Res. 2015;165(1):74-90. PMID: 24686037; doi: 10.1016/j.trsl.2014.03.001.
Yin J, Wang H, Vogel U, et al. Fine-mapping markers of lung cancer susceptibility in a sub-region of chromosome 19q13.3 among Chinese. Oncotarget. 2016;7(38):60929-39. PMID: 27183913; doi: 10.18632/ oncotarget.9279.
Qin H, Zhu J, Zeng Y, et al. Aberrant promoter methylation of hOGG1 may be associated with increased risk of non-small cell lung cancer. Oncotarget. 2017;8(5):8330-41. PMID: 28039450; doi: 10.18632/ oncotarget.14177.
Baglietto L, Ponzi E, Haycock P, et al. DNA methylation changes measured in pre-diagnostic peripheral blood samples are associated with smoking and lung cancer risk. Int J Cancer. 2017;140(1):50-61. PMID: 27632354; doi: 10.1002/ijc.30431.
Tan S, Sun C, Wei X, et al. Quantitative assessment of lung cancer associated with gene methylation in the peripheral blood. Exp Lung Res. 2013;39(4 5):182-90. PMID: 23614702; doi: 10.3109/01902148.2013.790096.
Woodson K, Mason J, Choi SW, et al. Hypomethylation of p53 in peripheral blood DNA is associated with the development of lung cancer. Cancer Epidemiol Biomarkers Prev. 2001;10(1):69-74. PMID: 11205492.
Kitkumthorn N, Tuangsintanakul T, Rattanatanyong P, Tiwawech D, Mutirangura A. LINE-1 methylation in the peripheral blood mononuclear cells of cancer patients. Clin Chim Acta. 2012;413(9-10):869-74. PMID: 22326975; doi: 10.1016/j.cca.2012.01.024.
Konecny M, Markus J, Waczulikova I, et al. The value of SHOX2 methylation test in peripheral blood samples used for the differential diagnosis of lung cancer and other lung disorders. Neoplasma. 2016;63(2):246-53. PMID: 26774146; doi: 10.4149/210_150419N208.
Powrózek T, Krawczyk P, Nicoś M, et al. Methylation of the DCLK1 promoter region in circulating free DNA and its prognostic value in lung cancer patients. Clin Transl Oncol. 2016;18(4):398-404. PMID: 26311076; doi: 10.1007/s12094-015-1382-z.
Sequenom. User guide EpiTYPER 96 Version 1.0 (Document Number: UG11570 R2.0 CO 110074), March 25, 2011.
Chen Z, Guo Z, Ma J, et al. Foxp3 methylation status in children with primary immune thrombocytopenia. Hum Immunol. 2014;75(11):1115 9. PMID: 25305033; doi: 10.1016/j.humimm.2014.09.018.
Davis A, Tao MH, Chen J, et al. No association between global DNA methylation in peripheral blood and lung cancer risk in nonsmoking women: results from a multicenter study in Eastern and Central Europe. Eur J Cancer Prev. 2018;27(1):1-5. PMID: 27045934; doi: 10.1097/ CEJ.0000000000000244.
Joehanes R, Just AC, Marioni RE, et al. Epigenetic Signatures of Cigarette Smoking. Circ Cardiovasc Genet. 2016;9(5):436-47. PMID: 27651444; doi: 10.1161/CIRCGENETICS.116.001506.
Li Y, Ahmad A, Sarkar FH. ASPP and iASPP: Implication in cancer development and progression. Cell Mol Biol (Noisy-le-Grand). 2015;61(6):2-8. PMID: 26518890.
Vogel U, Nexø BA, Tjønneland A, et al. ERCC1, XPD and RAI mRNA levels in lymphocytes are not associated with lung cancer risk in a prospective study of Danes. Mutat Res. 2006;593(1-2):88-96. PMID: 16054657; doi: 10.1016/j.mrfmmm.2005.06.021.
